Romania vs Saudi Arabia: Life science patents granted, by technology
Romania
14 patents
in 2023
Saudi Arabia
14 patents
in 2023
Romania rank
35th
Saudi Arabia rank
35th
Life science patents granted, by technology over time
- Romania
- Saudi Arabia
How they compare
Romania currently reports 14 patents against 14 patents in Saudi Arabia, a difference of 0 patents.
The two have swapped places 5 times across 21 shared years of data; in 1999 it was Romania ahead.
Romania ranks 35th and Saudi Arabia ranks 35th of 65 countries.
Romania has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Romania | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 63 patents | 5 patents | 58 patents | Romania |
| 2000s | 49.44 patents | 33.67 patents | 15.78 patents | Romania |
| 2010s | 29.5 patents | 7.75 patents | 21.75 patents | Romania |
| 2020s | 21.33 patents | 7.33 patents | 14 patents | Romania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Romania or Saudi Arabia?
- Romania, at 14 patents against 14 patents in Saudi Arabia as of 2023.
- What is the difference in life science patents granted, by technology between Romania and Saudi Arabia?
- 0 patents, with Romania ahead.
- How many years of comparable data are there for Romania and Saudi Arabia?
- 21 years are reported by both, from 1999 to 2023.
- How do Romania and Saudi Arabia rank globally for life science patents granted, by technology?
- Romania ranks 35th and Saudi Arabia ranks 35th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.